title: Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis.
abstract: Amyotrophic lateral sclerosis is a relentless and devastating adult-onset neurodegenerative disease with no known cure. In mice with amyotrophic lateral sclerosis, CD4+ T lymphocytes and wild-type microglia potentiate protective inflammatory responses and play a principal role in disease pathoprogression. Using this model, we demonstrate that endogenous T lymphocytes, and more specifically regulatory T lymphocytes, are increased at early slowly progressing stages, augmenting interleukin-4 expression and protective M2 microglia, and are decreased when the disease rapidly accelerates, possibly through the loss of FoxP3 expression in the regulatory T lymphocytes. Without ex vivo activation, the passive transfer of wild-type CD4+ T lymphocytes into amyotrophic lateral sclerosis mice lacking functional T lymphocytes lengthened disease duration and prolonged survival. The passive transfer of endogenous regulatory T lymphocytes from early disease stage mutant Cu2+/Zn2+ superoxide dismutase mice into these amyotrophic lateral sclerosis mice, again without ex vivo activation, were substantially more immunotherapeutic sustaining interleukin-4 levels and M2 microglia, and resulting in lengthened disease duration and prolonged survival; the stable disease phase was extended by 88% using mutant Cu2+/Zn2+ superoxide dismutase regulatory T lymphocytes. A potential mechanism for this enhanced life expectancy may be mediated by the augmented secretion of interleukin-4 from mutant Cu2+/Zn2+ superoxide dismutase regulatory T lymphocytes that directly suppressed the toxic properties of microglia; flow cytometric analyses determined that CD4+/CD25+/FoxP3+ T lymphocytes co-expressed interleukin-4 in the same cell. These observations were extended into the amyotrophic lateral sclerosis patient population where patients with more rapidly progressing disease had decreased numbers of regulatory T lymphocytes; the numbers of regulatory T lymphocytes were inversely correlated with disease progression rates. These data suggest a cellular mechanism whereby endogenous regulatory T lymphocytes are immunocompetent and actively contribute to neuroprotection through their interactions with microglia. Furthermore, these data suggest that immunotherapeutic interventions must begin early in the pathogenic process since immune dysfunction occurs at later stages. Thus, the cumulative mouse and human amyotrophic lateral sclerosis data suggest that increasing the levels of regulatory T lymphocytes in patients with amyotrophic lateral sclerosis at early stages in the disease process may be of therapeutic value, and slow the rate of disease progression and stabilize patients for longer periods of time.
authors: Department of Neurology, Methodist Neurological Institute, Suite ST-802, 6560 Fannin Street, Houston, TX 77030, USA.
authors: David R
authors: DR
authors: Beers
authors: Jenny S
authors: JS
authors: Henkel
authors: Weihua
authors: W
authors: Zhao
authors: Jinghong
authors: J
authors: Wang
authors: Ailing
authors: A
authors: Huang
authors: Shixiang
authors: S
authors: Wen
authors: Bing
authors: B
authors: Liao
authors: Stanley H
authors: SH
authors: Appel
references: PLoS One. 2008 Jul 23;3(7):e2740
references: 18648532
references: Nat Genet. 2010 May;42(5):392-9
references: 20348957
references: J Neuroimmunol. 2005 Feb;159(1-2):215-24
references: 15652422
references: J Neuroimmune Pharmacol. 2009 Dec;4(4):389-98
references: 19731042
references: Nat Immunol. 2005 Apr;6(4):345-52
references: 15785760
references: Nat Rev Immunol. 2010 Jul;10(7):490-500
references: 20559327
references: Neuron. 2009 Oct 15;64(1):110-22
references: 19840553
references: Nat Neurosci. 2006 Jul;9(7):917-24
references: 16732273
references: J Neuroimmunol. 2009 May 29;210(1-2):73-9
references: 19307024
references: Immunity. 2010 May 28;32(5):593-604
references: 20510870
references: Immunity. 2010 Jan 29;32(1):11-3
references: 20152167
references: Muscle Nerve. 2002 Oct;26(4):459-70
references: 12362410
references: Neuron. 1997 Feb;18(2):327-38
references: 9052802
references: Mol Cell Neurosci. 2006 Mar;31(3):427-37
references: 16337133
references: Nature. 2006 May 11;441(7090):235-8
references: 16648838
references: J Neurochem. 2007 Sep;102(6):2008-2019
references: 17555556
references: J Neurol Sci. 1994 Jul;124 Suppl:96-107
references: 7807156
references: Neurobiol Dis. 2004 Apr;15(3):601-9
references: 15056468
references: J Immunol. 2010 Mar 1;184(5):2261-71
references: 20118279
references: J Neurochem. 2006 Nov;99(4):1176-87
references: 17018025
references: Glia. 2010 Jan 15;58(2):231-43
references: 19672969
references: Science. 1994 Jun 17;264(5166):1772-5
references: 8209258
references: Ann Neurol. 2004 Feb;55(2):221-35
references: 14755726
references: J Neuroinflammation. 2006 Sep 27;3:27
references: 17005052
references: Glia. 2004 Nov 1;48(2):179-82
references: 15378658
references: Brain Behav Immun. 2011 Jul;25(5):1025-35
references: 21176785
references: Brain. 1995 Jun;118 ( Pt 3):707-19
references: 7600088
references: J Neuroimmunol. 2006 Oct;179(1-2):87-93
references: 16857270
references: J Leukoc Biol. 2007 Nov;82(5):1083-94
references: 17675560
references: Pediatr Res. 2009 Jun;65(6):619-24
references: 19218878
references: Arch Neurol. 1993 Jan;50(1):30-6
references: 8093428
references: FASEB J. 2010 Aug;24(8):3093-102
references: 20371618
references: Cell. 2008 May 30;133(5):775-87
references: 18510923
references: Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15558-63
references: 18809917
references: Brain Behav Immun. 2005 Mar;19(2):173-80
references: 15664790
references: Trends Immunol. 2010 Jan;31(1):7-17
references: 19879804
references: Neuron. 2006 Oct 5;52(1):39-59
references: 17015226
references: Science. 2006 Jun 2;312(5778):1389-92
references: 16741123
references: Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16021-6
references: 17043238
references: Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17913-8
references: 18997009
references: J Neurosci Methods. 2006 Mar 15;151(2):121-30
references: 16125247
references: Nat Neurosci. 2006 Jan;9(1):108-18
references: 16369483
references: Eur J Immunol. 2004 Dec;34(12):3434-45
references: 15549735
references: J Immunol. 2000 Feb 15;164(4):1705-12
references: 10657614
references: J Exp Med. 2010 May 10;207(5):1067-80
references: 20439540
references: J Neuroimmunol. 1999 Dec;100(1-2):124-39
references: 10695723
references: Neuromolecular Med. 2005;7(3):197-206
references: 16247180
references: Neurology. 2001 Oct 9;57(7):1282-9
references: 11591849
references: Nat Rev Neurol. 2010 Jul;6(7):405-10
references: 20531383
references: Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19446-51
references: 18042719
references: Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1083-93
references: 16624536
references: J Clin Invest. 2007 Oct;117(10):2913-9
references: 17853944
references: Neuron. 1995 Jun;14(6):1105-16
references: 7605627